市場調査レポート
商品コード
1404753

更年期の市場規模、シェア、動向分析レポート:治療別、地域別、セグメント予測、2024年~2030年

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (North America, Europe, Latin America), And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
更年期の市場規模、シェア、動向分析レポート:治療別、地域別、セグメント予測、2024年~2030年
出版日: 2023年11月24日
発行: Grand View Research
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

更年期市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の更年期市場規模は2024年から2030年にかけてCAGR 5.37%を記録し、2030年には244億米ドルに達すると予測されています。

閉経後症候群の有病率の上昇、更年期に関連する健康面に関する意識の高まり、女性向け健康アプリの採用率の高さなどの要因が市場成長を牽引すると予測されます。

市場は、HRTに対する栄養補助食品の利点を支持する調査の高まりによって牽引されると予測されます。ブラックコホシュ、レッドクローバー、大豆イソフラボン、アンベレンなどの成分を含む多くの栄養補助食品が市場で入手可能です。メーカー各社も、更年期症状に対応する新製品の開発に取り組んでいます。例えば、モルファス社は2023年に、更年期や更年期の最も差し迫った症状のいくつかに対処するためのサプリメント製品をいくつか発売しました。最初に発売された製品はFiberUsで、グアー繊維から作られた無香料の水溶性プレバイオティック繊維です。

栄養補助食品とOTC医薬品の需要は、医師の予約の遅れ、ホルモン補充療法の再延期、小売薬局やオンライン・チャネルからのOTC医薬品の容易な入手により、パンデミック後のシナリオで増加しました。しかし、規制の緩和と更年期に対する意識の高まりにより、市場は現在安定しつつあります。

ほてりや寝汗の治療を目的とした医薬品のFDA承認が急増していることも、市場の成長を後押しする大きな要因となっています。2023年5月、FDAは、更年期に個人がしばしば経験する寝汗やほてりに対処する新しい非ホルモン薬を承認しました。フェゾリネタントと呼ばれるこの処方薬は、ホルモン療法を受けることができず、乳がん生存者などの血管運動症状に悩む人々のために特別にデザインされました。この薬はVeozahというブランド名で販売されています。

更年期市場レポートハイライト

  • 治療法に基づくと、2023年には栄養補助食品治療セグメントが市場を独占し、予測期間中に最も急速な成長が見込まれます。同分野の成長は、高齢者人口の増加や革新的製品の発売など、いくつかの要因によるものと考えられます。例えば、2021年4月、韓国の栄養補助食品会社であるPulmuone社は、更年期に関連する症状の治療のために大豆とホップの抽出物を含む製品を発表しました。
  • OTC医薬品治療セグメントは、非ホルモン性製品とホルモン性製品に分類されます。更年期を迎えた女性は、市販の(OTC)ホルモン製品を使用することが多くなっています。このセグメントの主要製品には、局所プロゲステロン、イブプロフェン、デヒドロエピアンドロステロン(DHEA)、メラトニンなどがあります。
  • 2023年には北米が最大の売上シェアを占めました。食事に関する意識が高まっており、高齢女性の間で特定の栄養ニーズに対する需要が高まっています。
  • 2022年1月、Amyris, Inc.は、更年期の治療、女性の健康に関する調査、更年期に対する社会の理解増進に注力する女性創業企業MenoLabs, LLC.の資産を買収する独占契約を締結したと発表しました。
  • 2023年1月、女性の健康ブランドであるオーポジティブは、史上初の更年期グミ・ビタミンを発売し、更年期の女性に便利でおいしい方法で症状を管理できるようにしました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場動向と展望
  • 市場力学
    • 閉経を迎える女性の数が増加
    • 更年期とその治療についての意識の向上
    • 更年期治療における機会と革新の拡大
    • 栄養補助食品の利点を裏付ける調査の増加
  • 市場抑制要因分析
    • 更年期と製品の副作用に関連する社会的偏見
    • 明確に定義された規制の欠如
  • 事業環境分析
    • PESTLE分析
    • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 治療ビジネス分析

  • 更年期市場:治療変動分析
  • 栄養補助食品
  • OTC医薬品
    • ホルモン製品
    • 非ホルモン製品

第5章 地域ビジネス分析

  • 地域別閉経市場シェア、2023年と2030年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 企業の分類
  • 戦略マッピング
    • 合併・買収
    • コラボレーション
    • 新製品の発売
  • 参入企業の概要
    • Bayer AG
    • Theramex
    • Abbvie Inc.
    • Abbott
    • Pure Encapsulations, LLC
    • Dr. Reddy's Laboratories Ltd.
    • Rainbow Light
    • PADAGIS LLC
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. Global dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 4. Global OTC pharma products market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 5. North America menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 6. North America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 7. U.S. menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 8. U.S. menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 9. Canada menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 10. Canada menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 11. Europe menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 12. Europe menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 13. UK menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 14. UK menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 15. Germany menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 16. Germany menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 17. France menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 18. France menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 19. Italy menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 20. Italy menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 21. Spain menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 22. Spain menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 23. Austria menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 24. Austria menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 25. Asia Pacific menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 26. Asia Pacific menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 27. China menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 28. China menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 29. Japan menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 30. Japan menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 31. India menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 32. India menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 33. South Korea menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 34. South Korea menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 35. Latin America menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 36. Latin America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 37. Brazil menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 38. Brazil menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 39. Mexico menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 40. Mexico menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 41. Middle East & Africa (MEA) menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 42. Middle East & Africa (MEA) menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
  • Table 43. South Africa menopause market estimates and forecast, 2018 - 2030 (USD Million)
  • Table 44. South Africa menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig 1. Menopause market segmentation
  • Fig 2. Market research process
  • Fig 3. Information procurement
  • Fig 4. Primary research pattern
  • Fig 5. Market research approaches
  • Fig 6. Value - chain - based sizing & forecasting
  • Fig 7. QFD modeling for market share assessment
  • Fig 8. Market formulation & validation
  • Fig 9. Menopause market outlook 2023 (USD Million)
  • Fig 10. Penetration & growth prospect mapping
  • Fig 11. Market driver relevance analysis (Current & future impact)
  • Fig 12. Market restraint relevance analysis (Current & future impact)
  • Fig 13. Menopause market: Treatment movement analysis
  • Fig 14. Menopause market treatment outlook: Key takeaways
  • Fig 15. Dietary supplements market, 2018 - 2030 (USD Million)
  • Fig 16. OTC pharma products market, 2018 - 2030 (USD Million)
  • Fig 17. Hormonal products market, 2018 - 2030 (USD Million)
  • Fig 18. Non - hormonal products market, 2018 - 2030 (USD Million)
  • Fig 19. Regional marketplace: key takeaways
  • Fig 20. Regional outlook, 2023 & 2030
  • Fig 21. Global menopause market: region movement analysis
  • Fig 22. North America menopause market, 2018 - 2030 (USD Million)
  • Fig 23. U.S. key country dynamics
  • Fig 24. U.S. menopause market, 2018 - 2030 (USD Million)
  • Fig 25. Canada key country dynamics
  • Fig 26. Canada menopause market, 2018 - 2030 (USD Million)
  • Fig 27. Europe menopause market, 2018 - 2030 (USD Million)
  • Fig 28. UK key country dynamics
  • Fig 29. UK menopause market, 2018 - 2030 (USD Million)
  • Fig 30. Germany key country dynamics
  • Fig 31. Germany menopause market, 2018 - 2030 (USD Million)
  • Fig 32. France key country dynamics
  • Fig 33. France menopause market, 2018 - 2030 (USD Million)
  • Fig 34. Italy key country dynamics
  • Fig 35. Italy menopause market, 2018 - 2030 (USD Million)
  • Fig 36. Spain key country dynamics
  • Fig 37. Spain menopause market, 2018 - 2030 (USD Million)
  • Fig 38. Sweden key country dynamics
  • Fig 39. Sweden menopause market, 2018 - 2030 (USD Million)
  • Fig 40. Norway key country dynamics
  • Fig 41. Norway menopause market, 2018 - 2030 (USD Million)
  • Fig 42. Denmark key country dynamics
  • Fig 43. Denmark menopause market, 2018 - 2030 (USD Million)
  • Fig 44. Asia Pacific menopause market, 2018 - 2030 (USD Million)
  • Fig 45. Japan key country dynamics
  • Fig 46. Japan menopause market, 2018 - 2030 (USD Million)
  • Fig 47. China key country dynamics
  • Fig 48. China menopause market, 2018 - 2030 (USD Million)
  • Fig 49. India key country dynamics
  • Fig 50. India menopause market, 2018 - 2030 (USD Million)
  • Fig 51. Australia key country dynamics
  • Fig 52. Australia menopause market, 2018 - 2030 (USD Million)
  • Fig 53. Thailand key country dynamics
  • Fig 54. Thailand menopause market, 2018 - 2030 (USD Million)
  • Fig 55. South Korea key country dynamics
  • Fig 56. South Korea menopause market, 2018 - 2030 (USD Million)
  • Fig 57. Latin America menopause market, 2018 - 2030 (USD Million)
  • Fig 58. Brazil key country dynamics
  • Fig 59. Brazil menopause market, 2018 - 2030 (USD Million)
  • Fig 60. Mexico key country dynamics
  • Fig 61. Mexico menopause market, 2018 - 2030 (USD Million)
  • Fig 62. Argentina key country dynamics
  • Fig 63. Argentina menopause market, 2018 - 2030 (USD Million)
  • Fig 64. Middle East and Africa menopause market, 2018 - 2030 (USD Million)
  • Fig 65. South Africa key country dynamics
  • Fig 66. South Africa menopause market, 2018 - 2030 (USD Million)
  • Fig 67. Saudi Arabia key country dynamics
  • Fig 68. Saudi Arabia menopause market, 2018 - 2030 (USD Million)
  • Fig 69. UAE key country dynamics
  • Fig 70. UAE menopause market, 2018 - 2030 (USD Million)
  • Fig 71. Kuwait key country dynamics
  • Fig 72. Kuwait menopause market, 2018 - 2030 (USD Million)
  • Fig 73. Company market position analysis
  • Fig 74. Company/competition categorization
  • Fig 75. Strategy mapping
目次
Product Code: GVR-4-68039-434-2

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

  • Based on treatment, the dietary supplements treatment segment dominated the market in 2023 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
  • The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
  • North America held the largest revenue share in 2023. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
  • In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
  • In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Growing number of women undergoing menopause
    • 3.4.2. Increasing awareness about menopause and its treatment
    • 3.4.3. Growing opportunities and innovations in menopause treatment
    • 3.4.4. Increasing research supporting advantages of dietary supplements
  • 3.5. Market Restraint Analysis
    • 3.5.1. Social stigma associated with menopause and adverse effects of products
    • 3.5.2. Lack of well-defined regulations
  • 3.6. Business Environment Analysis
    • 3.6.1. PESTLE Analysis
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis

  • 4.1. Menopause Market: Treatment Movement Analysis
  • 4.2. Dietary Supplements
    • 4.2.1. Dietary Supplements Market, 2018 - 2030 (USD Million)
  • 4.3. OTC Pharma Products
    • 4.3.1. OTC Pharma Products Market, 2018 - 2030 (USD Million)
    • 4.3.2. Hormonal Products
      • 4.3.2.1.1. Hormonal Products Market, 2018 - 2030 (USD Million)
    • 4.3.3. Non-hormonal Products
      • 4.3.3.1.1. Non-hormonal Products Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Menopause Market Share By Region, 2023 & 2030
  • 5.2. North America
    • 5.2.1. North America Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Regulatory Framework/Scenario
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. U.S. Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Regulatory Framework/Scenario
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Canada Menopause Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Regulatory Framework/Scenario
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Germany Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Regulatory Framework/Scenario
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. UK Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Regulatory Framework/Scenario
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. France Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Regulatory Framework/Scenario
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Italy Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Regulatory Framework/Scenario
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Spain Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.7. Sweden
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Regulatory Framework/Scenario
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Sweden Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.8. Norway
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Regulatory Framework/Scenario
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Norway Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.9. Denmark
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Regulatory Framework/Scenario
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Denmark Menopause Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework/Scenario
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Japan Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework/Scenario
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. China Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework/Scenario
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. India Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Regulatory Framework/Scenario
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Australia Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.6. Thailand
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Regulatory Framework/Scenario
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Thailand Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.7. South Korea
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Regulatory Framework/Scenario
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. South Korea Menopause Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework/Scenario
      • 5.5.2.3. Competitive Scenario
      • 5.5.2.4. Brazil Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework/Scenario
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Mexico Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.4. Argentina
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework/Scenario
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Argentina Menopause Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. MEA Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework/Scenario
      • 5.6.2.3. Competitive Scenario
      • 5.6.2.4. South Africa Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework/Scenario
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Saudi Arabia Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework/Scenario
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. UAE Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework/Scenario
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Kuwait Menopause Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
    • 6.2.1. Merger& Acquisition
    • 6.2.2. Collaborations
    • 6.2.3. New Product Launch
  • 6.3. Participant's overview
    • 6.3.1. Bayer AG
      • 6.3.1.1. Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Theramex
      • 6.3.2.1. Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Abbvie Inc.
      • 6.3.3.1. Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Abbott
      • 6.3.4.1. Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Pure Encapsulations, LLC
      • 6.3.5.1. Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Dr. Reddy's Laboratories Ltd.
      • 6.3.6.1. Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Rainbow Light
      • 6.3.7.1. Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. PADAGIS LLC
      • 6.3.8.1. Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product Benchmarking
      • 6.3.8.4. Strategic Initiatives